**Neko Health Secures $700 Million to Expand AI-Powered Preventive Health Scans in the U.S.**
Neko Health, the AI-driven preventive healthcare company, has raised $700 million in a Series C funding round to expand its AI body scanning services in the United States, beginning with a clinic in New York. The company’s flagship offering combines medical imaging, blood tests, proprietary sensors, and clinician review to provide a comprehensive, non-invasive health assessment. The latest round positions Neko to accelerate its U.S. expansion while continuing to grow its presence across the UK and Sweden.
**How Neko Health’s AI Body Scans Work**
Neko operates specialized clinics that deliver a 60-minute, radiation-free health assessment using a combination of full-body scans, blood analysis, and advanced sensors. The service is designed to screen for early signs of conditions such as skin cancer, cardiovascular disease, and diabetes. The scan includes electrocardiograms, arterial measurements, body-composition analysis, and high-resolution skin imaging, with results reviewed in person with a medical professional.
The company’s model integrates proprietary technology with existing clinical practices, offering a bundled experience that emphasizes convenience and continuity. While individual components of the scan are available through other healthcare channels, Neko’s approach seeks to streamline access and interpretation under one roof.
**Funding Overview and Strategic Backers**
The Series C round was led by Lightspeed Venture Partners and co-led by O.G. Venture Partners. Returning investors Atomico, General Catalyst, and Lakestar participated alongside new backers such as Liberty City Ventures, Positive Sum, and BDT & MSD. Notable individual investors contributing to the round include Mark Zuckerberg, Priscilla Chan, Maria Sharapova, will.i.am, and Thierry Henry, as well as Reddit co-founder Alexis Ohanian and actress Zoë Saldaña.
David Ofer of O.G. Venture Partners will join Neko’s board, pending regulatory approval. The latest funding brings Neko’s total disclosed capital since 2023 to over $1 billion, with $65 million raised in a 2023 Series A round and $260 million in early 2025.
Neko plans to use the capital to open clinics in New York and additional U.S. cities. No specific locations or timelines have been disclosed, though a waitlist for the New York clinic is already active on the company’s website. Pricing for U.S. services has not been announced.
**Global Operations and Business Model**
Neko currently operates eight clinics across the UK and Sweden, offering scans at £299 in the UK and 2,750 Swedish kronor in Sweden, approximately $400 and $285 respectively. Since launching in 2023, the company has completed 100,000 scans, with over 350,000 registered users or waitlist members. According to internal data, 75% of customers book and prepay for a follow-up scan after their initial visit, enabling longitudinal tracking of health metrics.
Recent upgrades include enhanced body-composition tools, wearable-device data integration, and updated medical devices such as Derma, Echo, and Spectrum, which collect data on skin, heart function, and circulation. These improvements are part of Neko’s broader effort to automate more of the scanning process and increase data volume.
**U.S. Regulation and Clinical Approach**
Two of Neko’s internally developed devices have received 510(k) clearance from the U.S. Food and Drug Administration (FDA)—Derma-2 for telethermography and Spectrum-2 as a tissue-saturation oximeter. These approvals apply to specific devices and uses rather than an overall health screening service.
In the U.S., Neko positions itself as a preventive health and wellness provider rather than a full-service medical practice. Customers are advised to maintain regular care with their primary clinicians, and Neko refers complex findings to specialists. Its services are not currently covered by health insurance, and out-of-pocket payment is required.
**Clinical Evidence and Ongoing Evaluation**
Public records do not include a completed peer-reviewed study validating Neko’s full screening service. A ClinicalTrials.gov study is assessing the use of Neko’s multimodal skin imaging for conditions such as skin cancer and Raynaud’s phenomenon, but results are not yet conclusive regarding clinical performance.
The company’s reported outcomes come from 1,469 customers in Stockholm who completed a second scan approximately one year after their first. Improvements in blood pressure, cholesterol, and blood sugar were observed, though the analysis lacked a control group and was not peer-reviewed.
**Frequently Asked Questions (FAQ)**
**What does Neko Health’s AI body scan service include?**
Neko’s service combines medical imaging, blood tests, proprietary sensors, electrocardiograms, arterial measurements, body-composition analysis, and clinician review. The scan is designed to screen for signs of conditions such as skin cancer, cardiovascular disease, and diabetes.
**Where is Neko Health planning to expand in the United States?**
Neko is beginning its U.S. expansion with a clinic in New York, with plans to open additional locations in other U.S. cities in the future.
**How much do Neko Health scans cost in the U.S.?**
Pricing for U.S. services has not yet been announced. In the UK and Sweden, scans cost £299 and approximately $400 USD, respectively.
**Is Neko Health covered by insurance?**
No. Neko’s U.S. clinics do not currently participate with health insurance plans, and most services are not covered by payers.
**What regulatory approvals has Neko Health obtained in the U.S.?**
Two internal devices—Derma-2 and Spectrum-2—have received FDA 510(k) clearance. These approvals apply only to the specific devices and their stated uses.
**Are Neko Health’s AI systems used to make diagnoses?**
Neko states that AI supports the scanning and reporting process, but clinicians review all findings. The company does not claim that AI independently diagnoses medical conditions.
**Is there clinical evidence supporting Neko’s full screening service?**
Publicly available information does not include completed peer-reviewed studies validating the full service. An ongoing clinical trial is evaluating aspects of its imaging technology.
**Conclusion**
Neko Health’s $700 million funding round underscores strong investor confidence in its AI-powered preventive health model. By integrating imaging, blood testing, and clinician oversight into a single appointment, the company is expanding its footprint in the U.S. while refining its technology and service offering. However, questions regarding clinical validation, cost, and insurance coverage remain. As Neko prepares for broader U.S. deployment, the long-term impact of its approach on population health outcomes will depend on continued transparency, rigorous evaluation, and accessible design.
